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The infectious agents that have been identified as definitely or
probably carcinogenic to humans (Groups 1 and 2A) in the
International Agency for Research on Cancer (IARC) monograph
series are shown in Table 1. They include hepatitis B (HBV) and C
(HCV) viruses, human papillomaviruses (HPV), human immuno-
deficiency virus (HIV) and T-lymphotropic virus type-1 (HTLV-1),
Epstein–Barr virus (EBV) and human herpesvirus 8 (HHV8), and
the bacterium Helicobacter pylori.
In addition to these associations, there is substantial evidence
for a causative relationship between chronic infection with
hepatitis C virus (HCV) and non-Hodgkin lymphoma (NHL), an
association that has been the subject of several recent systematic
reviews (Gisbert et al, 2003; Matsuo et al, 2004; dal Maso and
Franceschi, 2006).
METHODS
Attributable fractions
For most infections, calculation of the population-attributable
fraction (PAF) relies on the classic formula for population-
attributable risk (Cole and Macmahon, 1971):
PAF ¼
pðr   1Þ
1 þ pðr   1Þ
where r represents the relative risk of exposure, and p its
prevalence in the population. The formula results in a proportion
that is applied to the total number of incident cases in the UK
population, to obtain the number of cases that can theoretically be
attributed to the factor in that population (PAF). Its application
requires identification of data on the prevalence of the exposure to
the ‘causative’ agents in the UK population, as well as the
corresponding relative risks. This method is used to estimate the
number of cancers due to HBV, HCV, H. pylori and HIV (NHL).
For EBV, the prevalence of relevant infection is hard to define,
as the virus infects almost everyone in childhood or adolescence
and persists in latent form in B-lymphocytes throughout life.
Clearly, agents other than EBV are essential co-factors in
carcinogenesis, and EBV-attributable cancers are defined as those
in which EBV-DNA can be demonstrated in tumour cells.
For the oncogenic HPVs, it is generally accepted that almost all
cancers of the cervix uteri are the result of infection (Walboomers
et al, 1999), so the AF is 100%. At other sites, the prevalence of
infection in normal subjects is hard to define, so use of the classic
Cole–MacMahon formula is inappropriate; as for EBV, the HPV-
attributable cancers are defined as those in which HPV-DNA can
be demonstrated in tumour cells.
RESULTS
Human papillomavirus
IARC (2005) considers that there is convincing evidence that
infection with HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 66
can lead to cervical cancer. For HPV 16, the evidence further
supports a causal role in cancer of the vulva, vagina, penis, anus,
oral cavity and oropharynx and a limited association with cancer
of the larynx and periungual skin. HPV 18 also shows a limited
association with cancer at most of these sites. Evidence for
associations of HPV types of genus beta with squamous-cell
carcinoma of the skin is limited for the general population. There
is some evidence that HPVs are involved in squamous-cell
carcinoma of the conjunctiva, but inadequate evidence for a role
of HPVs in cancer of the esophagus, lung, colon, ovary, breast,
prostate, urinary bladder, and nasal and sinonasal cavities.
With respect to cancer of the cervix, oncogenic HPV may be
detected by PCR in virtually all cases of cervix cancer, and it is
generally accepted that the virus is necessary for development of
cancer, and that all cases of this cancer can be ‘attributed’ to
infection (Walboomers et al, 1999).
With respect to squamous-cell cancers of the vulva and vagina,
carcinoma of the penis, and anal cancer, published studies do not
allow quantification of relative risk and infection prevalence,
because they are generally small in size, and usually do not include
comparable measurement of prevalence of infection at these sites
in normal subjects. In order to estimate attributable fractions,
therefore, approximate estimates of the proportion of cancer cases
infected with HPV in various series are used.
The prevalence of HPV in vaginal cancer is about 60–65% in
studies using PCR methodology (Daling et al, 2002; IARC, 2005);
an overall HPV prevalence of 63% is assumed. About 20–50% of
vulvar cancers contain oncogenic HPV DNA (Madeleine et al,
1997; Herrero and Munoz, 1999), but only the basaloid and warty
type that tends to be associated with vulvar intraepithelial *Correspondence: Professor DM Parkin; E-mail: d.m.parkin@qmul.ac.uk
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only 2–23% of the keratinizing carcinomas harbour HPV (Trimble
et al, 1996); an overall HPV prevalence of 40% is assumed. For anal
cancer, in a large series of cases from Denmark and Sweden, 95%
and 83% of cancers involving the anal canal in women and men,
respectively, were positive for oncogenic HPV (Frisch et al, 1999),
and an AF of 90% is assumed. For penile cancer, HPV DNA was
found in 30% of 71 cases of penile cancer from Brazil (Bezerra
et al, 2001) and in 42% of 148 cases from the USA and Paraguay
(Rubin et al, 2001); the AF is assumed to be 40%.
HPV has a role in the aetiology of a fraction of cancers of the
oral cavity and pharynx (Shah, 1998), although the major risk
factors are tobacco and alcohol. A review of more than 5000
tumours of the upper aerodigestive tract (Kreimer et al, 2005a)
found that prevalence of HPV DNA in specimens from Europe was
16.0% (95% CI, 13.4–18.8) for oral cancers, 28.2% (95% CI, 24.4–
32.2) for tumours of the oro-pharynx and 21.3% in squamous cell
carcinomas (SCCs) of the larynx. However, HPV may not be of
aetiological relevance in all such cases. Van Houten et al (2001)
found that only 45% of DNA-positive cases showed E6 mRNA
expression, indicative of viral activity. Kreimer et al (2005b)
observed that about 50% of head and neck cancers had a high viral
load of HPV, and serologic antibodies to HPV16 virus-like
particles and HPV16 E6 and E7 proteins were detected in most
of these cases. We assume therefore that 8% oral cancers, 14%
oropharyngeal cancers and 10.6% laryngeal cancers are HPV-
related.
HPV (any type) is estimated to be responsible for 5088 cancers
occurring in the UK in 2010 (1.6% of all cancers), comprising 2691
cervix cancers, 1685 cases of ano-genital cancer and 712 cases of
upper aerodigestive tract cancer (Table 2).
Helicobacter pylori
Helicobacter pylori was classified as being carcinogenic for humans
in 1994 (IARC, 1994a). It is considered to be causally associated
with both carcinoma of the stomach and gastric lymphoma.
Surveys of H. pylori show that prevalence gradually increases
with age. Several studies have suggested that this represents a
birth-cohort effect, with infection becoming progressively less
common in recent generations (Banatvala et al, 1993; Kosunen
et al, 1997; Roosendaal et al, 1997). In the UK the most
comprehensive data on prevalence derive from the serological
surveys of 10000 serum samples collected in England and Wales in
1986 and 1996 (Vyse et al, 2002). Prevalence was related to decade
of birth and increased from 4% in those born during the 1980s to
30% in those born before 1940; analysis by decade of birth showed
no significant difference between samples collected in 1986 and
1996. Estimated prevalence of active infection varied by region and
was highest in London.
We estimated prevalence in the UK population in 2000 from the
data provided by Vyse et al (2002), assuming that prevalence in
Scotland and Northern Ireland was the same as that observed in
the North of England (Figure 1).
Gastric carcinoma The most satisfactory evidence on the
magnitude of the risk is from prospective studies. Retrospective
case–control studies are limited in observing H. pylori infection
after the development of cancer. H. pylori tends to disappear as
intestinal metaplasia and atrophy develop, so that prevalence of
infection may be seriously under-estimated in cases, even if anti-H.
pylori antibody is used as an indicator of infection. Several case–
control studies nested within cohorts have now been published, in
which infection is evaluated in cases and controls before the onset
of disease. In a meta-analysis by the Helicobacter and Cancer
Collaborative Group (2001), including 12 prospective studies
yielding 1228 gastric cancer cases, the OR for the association
between H. pylori infection and the subsequent development of
gastric cancer was 2.36 (95% CI 1.98–2.81). Analysing cancers of
the gastric cardia, the most proximal portion of the stomach and
non-cardia separately, they found no increase in risk for cardia
cancers (OR 0.99), while the overall risk for non-cardia cancers
was 2.97 (95% CI 2.34–3.77). The risk varied with the interval
Table 1 Major human infection-associated malignancies
Malignancy Agent (group)
Carcinoma
Bladder Schistosoma haematobium (blood fluke)
Cervix HPV (papillomavirus)
Liver HBV (hepadnavirus)
HCV (flavivirus)
Bile duct Opisthorchis viverrini (liver fluke)
Nasopharynx EBV (herpesvirus)
Stomach Helicobacter pylori (bacterium)
Lymphoma
Adult T-cell HTLV-I (retrovirus)
Burkitt EBV (herpesvirus)
Hodgkin EBV (herpesvirus)
Sarcoma
Kaposi HHV8 (herpesvirus)
Abbreviations: EBV¼Epstein–Barr virus; HBV¼hepatitis B virus; HCV¼hepatitis C
virus; HHV8¼human herpesvirus 8; HPV¼human papillomavirus; HTLV-I¼human
T-cell lymphotropic virus type I. From Mueller et al (2005).
Table 2 Estimated numbers of HPV-related cancers, UK (2010)
Observed cases HPV-related
Male Female Male Female Excess attributable cases (PAF)
Upper aerodigestive cancers
Cervix uteri 2691 2691 2691 (100)
Oral cavity 2284 1421 183 114 296 (8.0)
Oropharynx 981 323 138 45 184 (14.1)
Larynx 1803 386 191 40 232 (10.6)
Anogenital cancers
Anus 364 621 328 559 887 (90.0)
Vulva 1128 451 451 (40.0)
Vagina 251 157 157 (62.5)
Penis 475 190 190 (40.0)
Total (8 sites) 5907 6821 1030 4058 5088 (40.0)
Abbreviations: HPV¼human papillomavirus; PAF¼population-attributable fraction (%).
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expected, if infection is progressively lost as gastric atrophy
develops). The increase in risk was 5.9-fold (95% CI 3.4–10.3) for
H. pylori positivity 10 years or more prior to diagnosis. The
associations were not related to histological type of gastric cancer
(intestinal vs diffuse) or sex.
The proportion of gastric cancer cases occurring at the cardia,
compared with elsewhere in the stomach, can be estimated from
cancer registry data from England (2007), and from the results of
11 registries throughout the UK in 1998–2005 (Curado et al, 2007).
In both sets, a variable proportion of gastric cancer cases (40–
65%) are registered without specification of subsite. However,
fitting a linear regression model of the proportion of cardia
cancers vs the proportion of unspecified registrations suggests
that mis-specification of site is more or less random. The predicted
proportion of cardia cancers (with zero non-specification) is
51.9% in men and 38.9% in women. Age-specific proportions in
the UK were estimated based on the distribution by age in England
(2007).
With a relative risk of 5.9 and prevalence of infection in 2000 (10
years earlier) as shown in Figure 1, the attributable fraction of non-
cardia gastric cancer cases in 2010 is 61% in men and 59% in
women. This represents 2231 cases, 29.2% of all stomach cancers
in men and 36.0% in women, or 0.7% of all cancers.
Gastric lymphoma One of the two large American cohort studies
of H. pylori also examined the incidence of gastric NHL and found
that these cases showed elevated titres of antibody to H. pylori
(Parsonnet et al, 1994). The relative risk was 6.3 (95% CI 2.0–
19.9). Gastric NHL is rather a rare tumour, comprising about 5% of
all NHL (Newton et al, 1997).
Assuming that 5% of NHL cases in UK are localised to the
stomach, there were about 580 new cases in 2010. With a relative risk
of 6, and the estimated prevalence of infection in 2000 (Figure 1),
2.8% of NHL cases (327) would be attributable to H. pylori.
Epstein–Barr virus
EBV is considered to be a group I carcinogen by IARC (1997), with
conclusive evidence with respect to carcinogenicity in Burkitt
lymphoma, NHL in immunosuppressed subjects, sino-nasal
angiocentric T-cell lymphoma, Hodgkin lymphoma and naso-
pharyngeal carcinoma. The evidence concerning other cancers for
which an association with EBV has been demonstrated (lympho-
epithelial carcinomas, gastric adenocarcinoma and smooth muscle
tumours in immunosuppressed subjects) was considered to be
inconclusive.
EBV and NHL Burkitt lymphoma: Burkitt lymphoma is a rare
cancer in UK. There were an estimated 158 new cases in 2010. In
North America and Europe, about one-fifth to one-third have demon-
strable virus in tumour tissue, or elevated antibody titres to EBV
(Lenoir et al, 1984; Gutierrez et al,1 9 9 2 ) .T h en u m b e r so fE B V -
attributable Burkitt lymphoma cases in UK is therefore about 39.
Other NHL: EBV can cause lymphoproliferative diseases in
individuals with immune dysfunction (Lenoir and Delecluse,
1989). Lymphomas arising in immunocompromised individuals
are relatively rare, except in the case of AIDS, some of which are
associated with EBV. The proportion of AIDS-related lymphomas
is estimated in the context of HIV-related cancers (below). The
proportion of NHLs that occur in immunocompromised indivi-
duals, excluding AIDS (hereditary, syndromes, iatrogenic), or are
cases of the rare EBV-associated sino-nasal angiocentric T-cell
lymphoma, is impossible to estimate. It must be a very small
(o1%) fraction of NHLs, so there is no numerical allowance for
these cases in the estimates.
EBV and Hodgkin lymphoma Case–control studies generally
demonstrate higher titres of anti-EBV antibodies in cases of
Hodgkin lymphoma than in controls (Evans and Gutensohn,
1984). In a large prospective study, Mueller et al (1989) found that
elevated antibody titres precede diagnosis by several years – the
actual relative risks (2.6 and 3.7 for IgG and IgA capsid antigens,
4.0 for EBNA and 2.6 for early antigen (diffuse)) and prevalence of
raised titres correspond to attributable risks of 30–45%.
Sensitive techniques are able to detect EBV nucleic acids in 25–
50% of Hodgkin lymphomas, where it is located in the Reed–
Sternberg cells (Weiss et al, 1989; Armstrong et al, 1992). The
association with EBV appears to depend upon age. In the
childhood age range about 80% of cases are EBV positive (Weinreb
et al, 1996), whereas in young adults the proportion is about 15%
(Jarrett et al, 1991). In older age groups, EBV positivity appears to
be relatively high (70–75%) (Jarrett et al, 1991; Gledhill et al,
1991). In part, this pattern is determined by the frequency of
different histological subtypes of Hodgkin lymphoma. The mixed
cellularity subtype predominates in childhood, while the nodular
sclerosing subtype accounts for the marked peak in young adults.
The frequency of EBV positivity is much greater (5–15-fold) in
mixed cellularity than in nodular sclerosing Hodgkin lymphoma.
Nevertheless, it seems that, even allowing for cell type, age (more
childhood cases are EBV positive) and level of socio-economic
development are independent predictors of the association (Glaser
et al, 1997). For the purposes of estimation, the attributable
fraction at ages 0–14 is taken to be 80%, 20% at ages 15–44, and
70% at ages 445. Of the UK total of 1709 new cases in 2010, 773, or
45.2% of the total, are estimated to be EBV related.
EBV and nasopharyngeal carcinoma The involvement of EBV in
nasopharyngeal cancer (NPC) appears to be with undifferentiated
carcinomas of the nasopharynx. In low-risk areas, about 10–25%
of NPC is of type 1 (keratinising), which is less often infected. It is
assumed that 90% of cases of the estimated 446 NPC cases
occurring in the UK in 2010 are infected, a total of 401 cases, or
5.8% of all cancers or of the oral cavity and pharynx.
Summary: EBV EBV is the third most important cancer-causing
infection in the UK, responsible for an estimated 1213 cases in 2010
(0.4% of cancers), comprising 773 cases of Hodgkin disease, 401
nasopharyngeal cancers and 39 Burkitt lymphoma cases.
Hepatitis viruses
The role of chronic infection with the viruses of hepatitis B and C
in the aetiology of liver cancer is well established (IARC, 1994b).
More recently, on the basis of a substantial number of case–
control and cohort studies, an association between HCV and NHL
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Figure 1 Estimated prevalence of Helicobacter pylori in the UK in 2000.
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Maso and Franceschi, 2006).
Prevalence of hepatitis B surface antigen (HBsAg) positivity and
HCV antibodies in the serum of the general population of UK is
unknown, as no true random survey results exist. Age-specific
prevalence is published for first-time blood donors (subjects found
to be positive are obviously excluded from becoming repeat
donors), although these are healthy individuals, with a prevalence
much lower than the average in the population. An estimate of the
prevalence of hepatitis C in adults (aged 15–59), based on a model
incorporating all relevant samples, was made for England in 2003
(HPA, 2006); this estimate had not been updated by the end of
2010. These data were assumed for UK, with an estimate of
prevalence at ages 460 based on sero-surveys of laboratory
samples in England and Wales in the 1990s (Balogun et al, 2002).
For hepatitis B, the estimated population prevalence, based on
sero-surveys of laboratory samples in England and Wales in 1996
(Gay et al, 1999), was used to adjust the observed age–sex-specific
prevalence data from blood donors in England in 1995–2008
(HPA, 2009), and further adjusted upwards, to allow for the rather
higher prevalence in blood donors in UK, compared with those in
England (HPA, 2009).
The estimated prevalences are shown in Figure 2.
HBV and HCV and liver cancer The IARC Monograph (1994b)
summarises the results of some 15 cohort studies and 65 case–
control studies worldwide, examining the association between
seropositivity for HBsAg, indicating chronic infection with HBV,
and the risk of hepatocellular carcinoma. The cohort studies yield
relative risk estimates of 5.3–148, while the majority of case–
control studies yield relative risk estimates between 3 and 30. Some
of these studies were able to address potential confounding by
aflatoxin, hepatitis C infection, alcohol drinking and tobacco
consumption, and the IARC Monograph (1994b) overall evaluation
assessed HBV as carcinogenic to humans. A recent meta-analysis
by Cho et al (2011) found an odds ratio for mono-infection with a
HBV of 13.5 for all 47 studies included, and 20.3 for the four
studies in low-prevalence areas (such as UK). A relative risk of 20
is assumed in the current analysis.
The magnitude of the risk of liver cancer associated with chronic
‘infection’ with HCV became evident as the results of studies using
second- and third-generation anti-HCV ELISA tests or detection of
HCV RNA (by reverse transcription polymerase chain reaction)
became available. In a meta-analysis of studies, Donato et al (1998)
estimated the relative risk in HCV antibody-positive subjects who
were HBsAg negative as 17.3. The more recent meta-analysis by
Cho et al (2011) found an odds ratio of 23.8 in seven studies from
low-prevalence countries. We assume a relative risk of 20 for HCV
infection.
Assuming relative risks of chronic infection by these viruses of
20, and that joint infection by both HBV and HCV is very rare, we
estimate the fraction of liver cancers attributable to the two viruses
to be just 15.9% (567 of 3568 cases). This represents 0.18% of
cancers in the UK in 2010.
HCV and NHL At least three meta-analyses (Gisbert et al, 2003;
Matsuo et al, 2004; dal Maso and Franceschi, 2006) have been
conducted to evaluate the strength of the relationship between
HCV and NHL. The most recent of these (dal Maso and Franceschi,
2006) gives a rather lower estimate for the relative risk (2.5) than
the earlier studies. However, as it considered all NHL (not just B-
cell neoplasms) and took into account differences in age between
cases and controls, it is probably the most valid estimate. A recent
report pooling the results of seven case–control studies (de
Sanjose et al, 2008) gave a similar result (odds ratio of 1.8). Using
the value of 2.5, and the estimated prevalence of HCV infection in
the UK in 2010 (Figure 2), one can estimate the fraction of NHL
attributable to HCV as just 0.5% (53 of 11602 cases).
HIV and HHV8
In 1996, an IARC working group concluded that HIV was
carcinogenic to humans, an assessment based on the strong link
between infection with the virus and two cancers: Kaposi sarcoma
(KS) and NHL (IARC, 1996). These two diseases, along with cancer
of the cervix, are considered to be ‘AIDS-defining conditions’ –
that is, a HIV-positive subject with these cancers is considered to
have AIDS (CDC, 1992). Subsequently, increased risks for several
other cancers have been reported. The most convincing data come
from a follow-up of cohorts of HIV-positive subjects, comparing
the occurrence of cancers with the number expected in the general
population. Such studies suggest increased risks of several cancers,
especially Hodgkin disease, anal cancer, seminoma, myeloma, and,
less certainly, cancers of the lip, brain and lung (Goedert et al,
1998; Frisch et al, 2001; Grulich et al, 2002).
The evaluation by IARC (1997) considered that the evidence for
a role of KSHV/HHV8 in the causation of KS was ‘compelling, but
as yet limited’. However, it is now generally accepted to be the
principal cause of the disease (Boshoff and Weiss, 2001). The effect
of HIV is probably through immunosuppression – allowing HHV-
8 to escape control and thereby increasing viral load, for example.
HIV/HHV8 and KS Prior to the epidemic of HIV/AIDS, KS was a
very rare cancer in the UK. Grulich et al (1992) calculated the
incidence in England and Wales in 1971–80 as 0.14 per million
(same in males and females).
Because of the enormous increase in risk in subjects infected
with HIV (1000–5000 times the risk in the general population
(Serraino et al, 1997)), the increasing incidence of KS was the first
obvious manifestation of the AIDS epidemic. Before 1990, up to a
third of AIDS cases developed KS at some point (Hoover et al,
1993; Lundgren et al, 1995). The introduction of antiretroviral
therapy (HAART) for treating HIV in adults has caused a decline
in the incidence of KS in Western countries (International
Collaboration on HIV and Cancer, 2000); in the USA, for example,
the incidence of KS in men aged 20–54 in the cancer registries
of the SEER program fell from 17.2 per 10
5 in 1990–1 to 2.4 in
2000–2001 (Ries et al, 2004).
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
45+
P
r
e
v
a
l
e
n
c
e
 
(
%
)
Age group
AB
Male
Female
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
60+
P
r
e
v
a
l
e
n
c
e
 
(
%
)
Age group
Male
Female
<25 25–35 35–44 15–29 30–44 45–59
Figure 2 Estimated age- and sex-specific prevalence of carriers of (A) HBsAG and (B) anti-HCV antibodies in the UK.
Cancer, lifestyle and environment in the UK in 2010
S52
British Journal of Cancer (2011) 105(S2), S49–S56 & 2011 Cancer Research UKThe estimated number of KS cases in UK in 2010 is 172. All
might be ascribed to infection with HHV-8. Based on the rates in
the pre-AIDS era (Grulich et al, 1992), the number of cases
expected was 10. The difference (162 cases) is considered to be
attributable to HIV infection, while all cases of KS are attributable
to infection with HHV-8.
HIV and NHL The increased frequency of NHL in AIDS was
noted in 1982 (Ziegler et al, 1982). Since then, the elevated risk has
been confirmed in studies in the United States and Europe
(Casabona et al, 1991; Beral et al, 1991). About 3% of AIDS cases
present with a lymphoma, but lymphomas may occur in up to 10%
of AIDS cases at some point. Almost all lymphomas in AIDS cases
are of B-cell type. The cohort study of Cote ´ et al. (1997) estimated
the excess risk in AIDS to be about 160 times that in HIV-negative
subjects. Risk is highest for high-grade lymphomas; especially
diffuse immunoblastic (relative risk¼630) and undifferentiated
Burkitt lymphomas (relative risk¼220). Extra nodal lymphomas
are more common in AIDS than usual (Beral et al, 1991), although
it is probably because of the great excess of CNS lymphomas (15-
fold increase); other extra nodal lymphomas are not in excess
(Cote ´ et al. 1997). Males are more commonly affected – but it could
be that this is simply because of risk-group differences.
EBV is present in two-thirds of AIDS-related lymphomas
(Hamilton–Dutoit et al, 1993) and may have an important role
in lymphomagenesis (IARC, 1996, 1997). The frequency varies by
lymphoma type – it is found in almost all CNS lymphomas, 70–
80% of immunoblastic lymphomas and 30–40% of small-cell/
Burkitt-type lymphomas.
The availability of HAART in recent years has resulted in a
decline in the risk of NHL in HIV-infected individuals; it fell from
0.62% per year in the pre-HAART era (1992–1996) to 0.36% when
HAART regimens were widely available (1996–1999) (Interna-
tional Collaboration on HIV and Cancer, 2000). In the USA, cohort
studies suggest that the relative risk of NHL in HIV-positive
subjects since the introduction of HAART is about 6.5 (Hessol
et al, 2004; Engels et al, 2008), and this figure is used to estimate
the attributable fraction.
The overall prevalence of HIV infection in the UK in 2009 was
estimated to be 2.89 per 1000 in men aged 15–59 and 1.46 per 1000
in women (HPA, 2010). Prevalence in childhood and those over 60
is much lower: 0.09 and 0.46 per 1000, respectively (HPA, 2010; UK
CGHSS, 2006).
Based on these estimated prevalences, and a relative risk of 6.5,
only 52 cases of NHL in men and 16 in women (69 total) would
have been attributable to HIV in 2010. The numbers seem small,
but they are broadly in line with the numbers of cases expected
based on observed incidence rates of NHL in HIV-positive subjects
in recent years – for example, 1.8 per 1000 in the Swiss cohort in
2002–6 (Polesel et al, 2008) and 0.97 in three US states in 1996–
2002 (Engels et al, 2008). With these rates, 120 cases of NHL would
have occurred in HIV-positive subjects in the UK, compared with
11 expected, an excess of 109.
HIV and other cancers Hodgkin lymphoma: Several prospective
studies suggest that the risk of Hodgkin lymphoma is increased
some 10-fold in HIV-infected subjects (Goedert et al, 1998; dal
Maso et al, 2001; Grulich et al, 2002). Case series document
unusually aggressive disease, including a higher frequency of the
unfavourable histological subtypes (mixed cellularity and lympho-
cyte depleted), advanced stages and poor therapeutic response
compared with the behaviour of HD outside of the HIV setting. It
is not clear whether most or all of these cases of Hodgkin
lymphoma are related to EBV, all of which have already been
attributed to infection with this virus. A separate calculation of
HIV-attributable cases has not been carried out.
HPV-associated cancers: HPV-associated malignancies – most
notably cancer of the cervix uteri and anal cancers – occur
frequently in patients with HIV infection and AIDS (Frisch
et al, 2000). In part, this may simply reflect the lifestyle
factors associated with both infections – HIV-positive individuals
are more likely to be infected by HPV. On the other hand, HIV
may alter the natural history of HPV-associated oncogenesis
through loss of immune control, facilitating infection with
HPV or enhancing its persistence in cells and therefore increasing
the development of squamous intraepithelial lesions (SIL).
These cancers have already been attributed to infection with
HPV.
HIV infection has been found to be associated with an increased
risk of conjunctival SCC in follow-up of cohorts of HIV-positive
subjects in the USA (Goedert and Cote ´, 1995; Frisch et al, 2001).
With a relative risk of 10, about 1% of cases might be attributable
to HIV, given the prevalence of infection in the UK. As only 23
cases of conjunctival cancer were registered in England in 2007, the
number of attributable cases is ignored.
Summary: HIV-related cancer In all, 172 cases of KS and 69 cases
of NHL were caused by HIV and/or HHV-8 in 2010. Of the KS
cases, 162 are attributed to infection with HIV.
Human T lymphotropic virus
The evidence for the causal role of HTLV-1 in acute T-cell
leukaemia/lymphoma (ATL) is compelling (IARC, 1996). Preva-
lence of HTLV infection in UK is available for first-time
blood donors (HPA, 2009). Overall, it is 4.7 per 100000 in men
and 10.7 per 100000 in women, strongly increasing with age.
Based on the recorded incidence of ATL (ICD 91.5) in England
in 2007, 25 cases would have been expected in the UK population.
Summary
Table 3 summarises the quantification of cancers attributable to
infections in the UK in 2010. The estimate is 3925 (2.5% of all
cancers) in men and 5820 (3.7% of all cancers) in women. Of the
total of 9745, the infectious agents making the largest contribution
are HPV (5088 cases, 1.6% of all cancers), H. pylori (2559 cases,
0.8%) and EBV (1213 cases, 0.4%).
The cancers for which an infectious aetiology is most important
are cervix uteri (2691 cases in 2010), stomach (2231) and the upper
aerodigestive tract (mouth, pharynx and larynx – 1113 cases).
DISCUSSION
Worldwide, 17.8% of all cancers are attributable to infections
(Parkin, 2006), with a higher percentage in developing countries
(26.3%), and an average of 7.7% in developed countries reflecting
the higher prevalence of infection with the major causative agents
(hepatitis viruses, HPV, H. pylori, HIV). The proportion in the UK
is around half of the average for developed countries, and
very similar to the estimate (3.5%) for the Netherlands (van Lier
et al, 2008).
The results are dependent on the assumptions made about
relative risk, and accuracy of the estimates of prevalence of
infection in the general population. For some of the associations –
especially in relation to HPV and anogenital cancers – the estimate
of attributable fraction was based on the proportion of tumours in
which the virus (as viral DNA) could be detected. The reason
is mainly that prevalence of infection in the same tissues of
normal individuals is usually unknown. This may overestimate
attributable fractions, by including some cancer cases in which
the presence of the virus was coincidental, without, for
example, expressing viral oncoproteins. The estimate of HPV-
attributable cancers of the oral cavity, pharynx and larynx attempts
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relevant infections (expressing E6 and E7 proteins, for example).
The estimate of infection-attributable cancer is a conservative
one. Some other associations between infections and human
cancers, for which there is reasonable evidence for causality, have
not been taken into account. EBV has been detected in several
types of cancer, other than those attributed to it in this analysis,
with the most suggestive evidence implicating it in the aetiology of
gastric cancer (Takada, 2002; Herrmann and Niedobitek, 2003).
Chlamydia trachomatis infection has been shown to increase the
risk of developing SCC of the cervix (Smith et al, 2004). In any
case, no case of cancer has been attributed to more than one
infectious agent, so that the numbers of infection-attributable
cases can be calculated for different populations. Thus, for
example, the risk of cancer of the cervix uteri may be increased
by HIV infection (Frisch et al, 2001) as well as C. trachomatis, but
as all cases are attributed to HPV, none are included as HIV-
related cancers. In addition, the estimates of relative risk for those
associations accepted as causal that have been used in the
calculations are deliberately modest. For example, the relative risk
of liver cancer due to infection with hepatitis B is based on
measurement of serum HBsAg. However, viral DNA can be found
in many liver cancers without evidence of infection based on HBs
antigenaemia or antibody to HCV (Paterlini et al, 1990). The
relative risk of non-cardia gastric cancer in relation to infection
with H. pylori that was used (5.9) may also be too modest; more
sensitive techniques for estimating the presence of H. pylori (for
example, by detecting bacterial DNA) have much higher relative
risks (Mitchell et al, 2008), but as the prevalence estimates are
based on the presence of anti-H. pylori antibody, we use the
relative risk estimates based on the same techniques. Accepting
that all non-cardia gastric cancers are caused by infection (H.
pylori and/or EBV) as well as 10% of NHL are caused by HCV
(independent of HIV) would not, however, greatly change the
overall estimate.
See acknowledgements on page Si.
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Table 3 Estimated numbers of cancers attributable to different infectious agents, UK 2010
Estimated number of cancer cases by infectious agent
Cancer site HPV H. pylori EBV HBV and HCV HIV and KSHV HTLV
Excess attributable
cases (PAF)
Males
Oral cavity and pharynx 321 241 562 (0.35)
Larynx 191 191 (0.12)
Stomach 1304 1304 (0.82)
Anus 328 328 (0.21)
Liver 446 446 (0.28)
Kaposi 147 147 (0.09)
External genitalia 190 190 (0.12)
Non-Hodgkin lymphoma 182 31 38 52 12 316 (0.20)
Hodgkin lymphoma 442 442 (0.28)
Total 1030 1486 713 484 200 12 3925
% of all cancer
a 0.65 0.94 0.45 0.31 0.13 0.01 2.5%
Females
Oral cavity and pharynx 159 160 319 (0.21)
Larynx 40 40 (0.03)
Stomach 927 927 (0.60)
Anus 559 559 (0.36)
Liver 121 121 (0.08)
Kaposi 25 25 (0.02)
Cervix uteri 2691 2691 (1.73)
External genitalia 608 608 (0.39)
Non-Hodgkin lymphoma 145 9 14 16 13 197 (0.13)
Hodgkin lymphoma 331 331 (0.21)
Total 4058 1072 501 135 41 13 5820
% of all cancers
a 2.61 0.69 0.32 0.09 0.03 0.01 3.7%
Persons
Oral cavity and pharynx 480 401 881 (0.28)
Larynx 232 232 (0.07)
Stomach 2231 2231 (0.71)
Anus 887 887 (0.28)
Liver 567 567 (0.18)
Kaposi 172 172 (0.05)
Cervix uteri 2691 2691 (0.86)
External genitalia 798 798 (0.25)
Non-Hodgkin lymphoma 327 39 53 69 24 513 (0.16)
Hodgkin disease 773 773 (0.25)
Total 5088 2559 1213 619 241 24 9745
% of all cancers
a 1.62 0.81 0.39 0.20 0.08 0.01 3.1%
Abbreviations: EBV¼Epstein–Barr virus; H. pylori¼Helicobacter pylori; HBV and HCV¼hepatitis B and C viruses; HIV and KSHV¼human immunodeficiency virus and human
herpesvirus 8/Kaposi sarcoma; HPV¼human papillomaviruses; HTLV¼human T lymphotropic virus type 1; PAF¼population-attributable fraction.
aExcluding non-melanoma
skin cancer.
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